Pipobroman |
|
| Trade names | Vercite, Vercyte |
|---|
| AHFS/Drugs.com | International Drug Names |
|---|
| ATC code | |
|---|
|
3-bromo-1-[4-(3-bromopropanoyl) piperazin-1-yl]-propan-1-one
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| IUPHAR/BPS | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C10H16Br2N2O2 |
|---|
| Molar mass | 356.058 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
O=C(N1CCN(C(=O)CCBr)CC1)CCBr
|
InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2 YKey:NJBFOOCLYDNZJN-UHFFFAOYSA-N Y
|
| (verify) |
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent,[1] and is marketed in France and Italy.[2]
References
- ^ Passamonti F, Lazzarino M (September 2003). "Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman". Leukemia & Lymphoma. 44 (9): 1483–8. doi:10.3109/10428190309178768. PMID 14565648.
- ^ "Pipobroman". Drugs.com.
Intracellular chemotherapeutic agents / antineoplastic agents (L01) |
|---|
SPs/MIs (M phase) | | Block microtubule assembly | |
|---|
| Block microtubule disassembly |
- Taxanes (Cabazitaxel
- Docetaxel#
- Larotaxel
- Ortataxel†
- Paclitaxel#
- Tesetaxel)
- Epothilones (Ixabepilone)
|
|---|
|
|---|
DNA replication inhibitor | DNA precursors/ antimetabolites (S phase) | | Folic acid | |
|---|
| Purine | |
|---|
| Pyrimidine |
- DNA polymerase inhibitor (Cytarabine# +daunorubicin)
|
|---|
| Deoxyribonucleotide | |
|---|
|
|---|
Topoisomerase inhibitors (S phase) | | I |
- Camptotheca (Belotecan
- Camptothecin
- Cositecan†
- Etirinotecan pegol†
- Exatecan
- Gimatecan
- Irinotecan#
- Lurtotecan‡
- Rubitecan‡
- Silatecan§
- Topotecan)
|
|---|
| II | |
|---|
| II+Intercalation | |
|---|
|
|---|
Crosslinking of DNA (CCNS) | | Alkylating | |
|---|
| Platinum-based | |
|---|
| Nonclassical | |
|---|
| Intercalation | |
|---|
|
|---|
|
|---|
| Photosensitizers/PDT | |
|---|
| Other | | Enzyme inhibitors |
- FI (Tipifarnib§)
- CDK inhibitors (Abemaciclib
- Alvocidib†
- Palbociclib
- Ribociclib
- Seliciclib†)
- PrI
- PhI (Anagrelide)
- IMPDI (Tiazofurin§)
- LI (Masoprocol)
- PARP inhibitor (Fuzuloparib
- Niraparib +abiraterone acetate
- Olaparib
- Rucaparib)
- HDAC (Belinostat
- Entinostat
- Panobinostat
- Romidepsin
- Vorinostat)
- PIKI (Pi3K) (Alpelisib
- Copanlisib‡
- Duvelisib
- Idelalisib
- Inavolisib
- Umbralisib‡)
- IDH (Enasidenib
- Ivosidenib
- Olutasidenib
- Vorasidenib)
|
|---|
| Receptor antagonists | |
|---|
| Other/ungrouped |
- Adagrasib
- Aflibercept
- Arsenic trioxide# (Realgar/Indigo naturalis#)
- Asparagine depleters (Asparaginase#/Pegaspargase)
- Axicabtagene ciloleucel
- Belzutifan
- Bexarotene
- Brexucabtagene autoleucel
- Calaspargase pegol
- Celecoxib
- Ciltacabtagene autoleucel
- Darinaparsin
- Demecolcine
- Denileukin diftitox
- Eflornithine
- Elesclomol§
- Elsamitrucin
- Epacadostat
- Eribulin
- Estramustine
- Glasdegib
- Idecabtagene vicleucel
- Idroxioleic acid
- Imetelstat
- Lifileucel
- Lisocabtagene maraleucel
- Lonidamine
- Lucanthone
- Lurbinectedin
- Mitoguazone
- Mitotane
- Nadofaragene firadenovec
- Navitoclax
- Nirogacestat
- Obecabtagene autoleucel
- Oblimersen†
- Omacetaxine mepesuccinate
- Para-toluenesulfonamide
- Pelabresib
- Plitidepsin
- Retinoids (Alitretinoin
- Tretinoin#)
- Selinexor
- Sitimagene ceradenovec
- Sotorasib
- Tabelecleucel
- Tagraxofusp
- Talimogene laherparepvec
- Tazemetostat
- Tebentafusp
- Tiazofurine
- Tigilanol tiglate
- Tisagenlecleucel
- Trabectedin
- Veliparib
- Venetoclax
- Verdinexor
- Vosaroxin
|
|---|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|